Market-Moving News for April 10th
$ABVC
$ADIL
$NA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/14/2024 | $8.00 | Buy | Rodman & Renshaw | |
| 10/13/2021 | $12.00 | Buy | Brookline Capital | |
| 6/29/2021 | $5.00 | Buy | Litchfield Hills |
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation incorporates Senate Report 119-55, which includes a significant Congressional directive to the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA) to collaborate on
GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the "Reverse Split") of its common stock, par value $0.001 per share ("Common Stock"), that will become effective on February 5, 2026 at 11:59 p.m. Eastern Time (the "Effective Time"). Adial's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "ADIL" and will begin trading on a split-adjusted basis when the Nasdaq opens o
GLEN ALLEN, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the Company's lead investigational genetically targeted serotonin-3 receptor antagonist therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, once granted, is expected to protect Adial's core assets through at least 2045. Cary Claiborne,
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00
Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
PRE 14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
HONG KONG, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider, today announced the results of the Company's Annual General Meeting ("AGM") held at 10 A.M. on December 30, 2025, Beijing time (9 P.M., December 29, 2025, U.S. Eastern time). The proposals submitted for shareholder approval at the AGM have been approved. Specifically, the shareholders have passed the following resolutions: 1) to authorize (a) a share consolidation of every ten shares with a par value of US$0.002 each in the Company's issued and unissued share capital into one share with a par value of US$0.02 (the "Sh
HONG KONG, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider, today announced that it will hold its 2025 Annual General Meeting of Shareholders (the "2025 Annual Meeting") at 10 A.M. on December 30, 2025, Beijing time (9 P.M. on December 29, 2025, U.S. Eastern time) in 12F, China Yuangu Hanggang Technology Building, 509 Qianjiang Road, Shangcheng District, Hangzhou, Zhejiang, 310000, People's Republic of China. The Company has established the close of business on December 4, 2025, Eastern time (the "Record Date"), as the record date for determining shareholders entitled to notice
HONG KONG, July 24, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider in China, today announced the appointment of Ms. Can Yang as senior vice president of its wholly-owned subsidiary, Nano bit HK Limited ("Nano bit"). Ms. Yang will be responsible for leading the execution of Nano bit's digital currency strategic reserves initiatives and supporting its steady and sustainable growth within the global crypto financial ecosystem. Ms. Yang brings more than 15 years of experience in finance and investment, spanning both fields of Web2 industries and crypto assets sector. Since 2018, she has
HONG KONG, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider, today announced its unaudited financial results as of June 30, 2025 and for the first half of 2025 then ended. First Half of 2025 Financial Summary Net revenue was RMB8.3 million (US$1.2 million) for the first half of 2025, compared to RMB24.7 million in the same period of 2024.Gross loss was RMB10.7 million (US$1.5 million) for the first half of 2025, compared to a gross profit of RMB30.1 thousand in the same period of 2024.Loss from operations was RMB38.0 million (US$5.3 million) for the first half of 2025, com
HONG KONG, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider, today announced that it will report its unaudited financial results for the six months ended June 30, 2025 before the U.S. market opens on Friday, August 15, 2025. The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Hong Kong Time) on August 15, 2025. For participants who wish to join the call, please access the link provided below to complete the online registration process. Registration Link: https://s1.c-conf.com/diamondpass/100
HONG KONG, March 25, 2025 /PRNewswire/ -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced its unaudited financial results as of December 31, 2024 and for the six months ended December 31, 2024. Second Half of 2024 Financial Highlights Net revenue was RMB15.9 million (US$2.2 million) for the second half of 2024, compared to RMB26.1 million in the same period of 2023.Gross profit was RMB11.6 million (US$1.6 million) for the second half of 2024, compared to a gross loss of RMB40.6 million in the same period of 2023.Loss from operations was RMB39.8 million (US$5.5 million)
SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13D/A - Nano Labs Ltd (0001872302) (Subject)